Apolipoproteins Quantified Using Blood Volumetric Absorptive Microsampling and High-Throughput Mass Spectrometry for Risk Assessment in Ischemic Heart Disease

Circulation. 2024 Mar 19;149(12):970-972. doi: 10.1161/CIRCULATIONAHA.123.066034. Epub 2024 Mar 18.

Authors

Affiliations

¹ Barbra Streisand Women's Heart Center, Smidt Heart Institute, Los Angeles, CA (P.M., A.K., S.C., C.S., C.N.B.M., J.E.V.E.).
² Advanced Clinical Biosystems Research Institute, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA (K.M., M.M., I.B., D.M., Q.F., J.E.V.E.).
³ Cedars-Sinai Center for Outcomes Research and Education, Cedars-Sinai Medical Center, Los Angeles, CA (B.S.).

^# Contributed equally.

PMID: 38498608
PMCID: PMC10954092 (available on 2025-03-19)
DOI: 10.1161/CIRCULATIONAHA.123.066034

No abstract available

Keywords: C-reactive protein; apolipoproteins; mass spectrometry; pro-brain natriuretic peptide (1-76); troponin.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Apolipoproteins
Humans
Myocardial Ischemia* / diagnosis
Risk Assessment
Tandem Mass Spectrometry* / methods

Substances

Apolipoproteins

Grants and funding